Temozolomide-nicotinic acid eutectic crystal as well as preparation method and application thereof

By forming a co-crystal with temozolomide and niacin at a 1:1 molar ratio, the problem of insufficient solubility and stability in temozolomide water is solved, and the solubility and stability are improved. It is suitable for the treatment of brain gliomas, simplifying the preparation process and reducing the cost.

CN118994166APending Publication Date: 2024-11-22LUWAN BRANCH OF RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411076896.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The poor solubility and insufficient stability in water of temozolomide lead to a slow rate of in vitro dissolution of oral preparations, affecting the safety and efficacy of drug absorption and clinical use.

Method used

The eutectic crystal was formed by 1:1 molar ratio of temozolomide and niacin. It was prepared by grinding method to improve its solubility and chemical stability, and verified it in Cu-Kα ray powder diffraction, differential scanning calorimetry analysis and thermogravimetric analysis. New phases are generated.

Benefits of technology

It improves the solubility and chemical stability of temozolomide in water, reduces production, storage and transportation costs, simplifies the preparation process, is suitable for drugs for treating brain gliomas, and extends the oral half-life of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994166A_ABST
    Figure CN118994166A_ABST
Patent Text Reader

Abstract

The invention discloses a temozolomide-nicotinic acid eutectic crystal, which takes temozolomide as an active pharmaceutical ingredient and nicotinic acid as a eutectic crystal precursor. The temozolomide-nicotinic acid eutectic crystal is formed by combining temozolomide and nicotinic acid according to a molar ratio of 1: 1. The temozolomide-nicotinic acid eutectic crystal provided by the invention can effectively reduce the production, storage and transportation costs, and can be prepared by a grinding method, the grinding method can greatly shorten the time, and the method is simple and easy to operate, low in cost and convenient for large-scale popularization in industrial pharmacy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical chemistry and crystallization technology, and specifically relates to a temozolomide-nicotinic acid cocrystal and a preparation method and application thereof. Background Art

[0002] Gliomas are a type of malignant tumor that is extremely harmful and prone to occur frequently. Currently, surgical treatment of gliomas can remove the tumor to the greatest extent, but since most gliomas have the characteristics of invasive growth and malignant lesions, the postoperative recurrence rate is high. Clinical studies have shown that chemotherapy can prolong the survival of glioma patients after surgery and radiotherapy.

[0003] Temozolomide (TMZ) is a new second-generation alkylating agent developed by Schering-Plough for the treatment of glioblastoma multiforme or anaplastic astrocytoma. It was approved for marketing by the European Medicines Agency (EMEA) on January 20, 1999, and its approved indications are glioblastoma multiforme (brain cancer) that has progressed or recurred after conventional treatment; it was approved for marketing by the U.S. Food and Drug Administration (FDA) on August 11, 1999, and its approved indications are glioblastoma multiforme and degenerative astrocytoma, etc. It has been rated as the "gold standard drug" for the treatment of malignant glioma by the American and European medical communities.

[0004] Temozolomide is an alkylating anti-tumor drug containing an imidazole tetrazine ring. Its chemical name is 3,4-dihydro-3-methyl-4-oxoimidazolo[5,1-d]-asymmetric-tetrazolyl-8-amide, and its chemical structure is shown below:

[0005]

[0006] Temozolomide is a prodrug and has no activity itself. It is converted into the active compound MITC (5-(3-methyltriazene-1-yl) imidazole-4-amide) through non-enzymatic pathways at physiological pH levels. The latter is further hydrolyzed into AIC (5-amino-imidazole-4-amide) and methyldiazonium ions. Subsequently, the methyldiazonium ions methylate DNA by acting on the O6 and N7 sites on guanine, making it unable to pair with thymine and produce cytotoxicity, exerting anti-tumor activity. The drug can pass through the blood-brain barrier, so it has a good effect on brain tumors, and also has obvious effects on leukemia, melanoma, lymphoma and solid tumors.

[0007] Temozolomide is a white or light brown or light pink powder, odorless, slightly soluble in water and dimethyl sulfoxide, and soluble in hot water. The stability of the raw material is poor, stable under the condition of pH <5, and easily decomposed at pH>7. Due to the poor solubility of temozolomide in water, about 3.1 mg / mL, and the slow dissolution rate, the in vitro dissolution behavior of oral preparations is the limiting step affecting in vivo absorption. Most of the oral preparations on the market are ordinary preparations with a slow in vitro dissolution rate (45 minutes dissolution of more than 85%). At the same time, due to the poor stability, the product needs to be stored at 2°C-25°C, which is not conducive to ensuring product quality and brings inconvenience and risks to clinical use. In order to ensure the safety and efficacy of temozolomide, it is urgent to improve its stability and extend its oral half-life.

[0008] Niacin is also known as Vitamin B 3 , widely found in various animal and plant foods, is one of the essential vitamins for the human body. As a drug, niacin participates in the energy metabolism of carbohydrates, fats and proteins in the body's cells, and plays an important role in the redox reaction of body tissues. At the same time, niacin has the function of lowering cholesterol levels and dilating blood vessels, and has the effect of protecting collagen fibers in the skin and the normal function of digestive organs. It can be used to prevent and treat vitamin deficiency diseases such as pellagra.

[0009] Pharmaceutical cocrystals are crystals formed by combining active pharmaceutical ingredients and suitable cocrystal reagents through hydrogen bonds or other non-covalent bonds using the principles of crystal engineering, pharmaceutical science, supramolecular chemistry, and self-assembly. As a new drug crystal form, the formation of cocrystals can change the physical and chemical properties of drugs and improve clinical efficacy without destroying the covalent bonds of drugs. It can not only ensure the stability of drugs, but also greatly change other aspects such as melting point and solubility. In addition, after the formation of cocrystals, some pharmacokinetic parameters of drugs can also be changed, such as C max (peak plasma concentration), T max (peak time), t 1 / 2 (elimination half-life) and AUC (area under the plasma concentration-time curve), etc. When two drugs form a cocrystal, the purpose of combined medication can be achieved while improving the physicochemical properties and pharmacokinetic parameters of both drugs.

[0010] The patent application with publication number WO2011036676A3 discloses a novel temozolomide drug cocrystal using a cocrystal coformer selected from aliphatic and aromatic carboxylic acids in a fixed stoichiometric ratio. Compared with the pure drug, the novel temozolomide-carboxylic acid cocrystal exhibits improved hydrolytic stability and good water dissolution rate. Specifically disclosed is the formation of cocrystals of temozolomide with the following acids: formic acid, acetic acid, oxalic acid, citric acid, succinic acid, salicylic acid, d, l-malic acid, d, l-tartaric acid, maleic acid, fumaric acid, cinnamic acid, malonic acid, benzoic acid, crotonic acid, p-hydroxybenzoic acid, p-aminobenzoic acid, propionic acid, sorbic acid, linoleic acid, adipic acid, lactic acid, glutaric acid, aconitic acid, and anthranilic acid. Summary of the invention

[0011] The purpose of the present invention is to provide a temozolomide-nicotinic acid cocrystal.

[0012] Another object of the present invention is to provide a method for preparing the temozolomide-nicotinic acid cocrystal.

[0013] Another object of the present invention is to provide a use of the temozolomide-nicotinic acid cocrystal in the preparation of a drug for treating brain glioma.

[0014] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0015] In a first aspect, the present invention provides a temozolomide-nicotinic acid cocrystal, which uses temozolomide as a pharmaceutically active ingredient and nicotinic acid as a cocrystal precursor.

[0016] The temozolomide-nicotinic acid cocrystal is formed by combining temozolomide and nicotinic acid in a molar ratio of 1:1.

[0017] The X-ray powder diffraction (PXRD) spectrum of the temozolomide-nicotinic acid cocrystal measured by Cu-Kα radiation has characteristic peaks at diffraction angles 2θ of approximately 14.66±0.2°, 15.42±0.2°, 26.54±0.2°, and 28.75±0.2°.

[0018] In the PXRD spectrum, the temozolomide-nicotinic acid cocrystal has characteristic peaks at 2θ angles of approximately 10.83±0.2°, 14.66±0.2°, 15.42±0.2°, 17.96±0.2°, 19.07±0.2°, 24.78±0.2°, 25.95±0.2°, 26.54±0.2°, 26.88±0.2°, 27.96±0.2°, 28.75±0.2°, 29.81±0.2°, and 37.99±0.2°.

[0019] In the differential scanning calorimetry (DSC) graph of the temozolomide-nicotinic acid co-crystal, there is a characteristic melting peak at about 199.7±2° C. (onset temperature).

[0020] Thermogravimetric analysis (TGA) of the temozolomide-nicotinic acid cocrystal showed the following: it began to lose weight at about 140° C. and lost 71% of its weight at about 400° C.

[0021] The second aspect of the present invention provides a method for preparing the temozolomide-nicotinic acid cocrystal, comprising the following steps:

[0022] Temozolomide and nicotinic acid are mixed at a molar ratio of 1:1, an organic solvent is added, and the mixture is ground with grinding balls to obtain the temozolomide-nicotinic acid cocrystal.

[0023] The organic solvent is selected from at least one of ethanol, methanol, isopropanol, tetrahydrofuran, acetone and acetonitrile.

[0024] The mass ratio of the mass of the organic solvent to the total mass of temozolomide and nicotinic acid is 0.001 to 0.3:1 (preferably 0.1:1, 0.15:1, 0.11:1).

[0025] The grinding is to put a grinding pot containing temozolomide, nicotinic acid and an organic solvent into a planetary ball mill for grinding.

[0026] The conditions of the planetary ball mill are as follows: the rotation speed is set to 100-1000 rpm (preferably 500 rpm, 600 rpm, 400 rpm), the grinding time is set to 1-5 minutes (preferably 5 minutes, 4 minutes), the interval is 1-5 minutes (preferably 3 minutes, 2 minutes, 1 minute), and the cycle is 1-5 times (preferably 5 times, 3 times).

[0027] The mass of the grinding balls is 2 to 100 times (preferably 20, 22.8, 25 times) the total mass of temozolomide and nicotinic acid.

[0028] The third aspect of the present invention provides a use of the temozolomide-nicotinic acid cocrystal in the preparation of a drug for treating brain glioma.

[0029] In the drug for treating brain glioma, the temozolomide-nicotinic acid cocrystal should be an effective dose.

[0030] The brain glioma is selected from glioblastoma multiforme and degenerative astrocytoma.

[0031] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0032] The temozolomide-nicotinic acid cocrystal provided by the present invention can effectively reduce the production, storage and transportation costs, and can be prepared by a grinding method, which can greatly shorten the time. This method is simple and easy to operate, low in cost, and easy to promote on a large scale in industrial pharmaceuticals.

[0033] Based on the deficiencies of temozolomide in solubility, stability and compressibility, the present invention provides a temozolomide-nicotinic acid cocrystal, wherein the molar ratio of temozolomide to nicotinic acid is 1:1, thereby improving its solubility and chemical stability, and effectively reducing the production, storage and transportation costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 is the X-ray powder diffraction (PXRD) pattern of the temozolomide-nicotinic acid co-crystal of Example 1.

[0035] Figure 2 is a differential scanning calorimetry (DSC) chart of the temozolomide-nicotinic acid co-crystal of Example 1.

[0036] Figure 3 is a thermogravimetric analysis (TGA) chart of the temozolomide-nicotinic acid co-crystal of Example 1. DETAILED DESCRIPTION

[0037] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0038] The detection instrument and method used in the present invention are:

[0039] The instrument used for X-ray powder diffraction (PXRD) is Bruker D8 Advance diffractometer, using Cu Kα radiation, voltage of 40 kV, and current of 40 mA. The instrument was calibrated with the standard sample that came with the instrument before use. The acquisition software was Diffrac Plus XRD Commander, and the analysis software was MDI Jade 6.0. The samples were tested at room temperature, and the samples to be tested were placed on organic glass slides. The detailed test conditions are as follows: 2θ angle range: 3-40°; step length: 0.02°; speed: 0.1 sec / step. Unless otherwise specified, the samples were not ground before testing.

[0040] Differential scanning calorimetry (DSC) data were collected from a Mettler Toledo DSC1 differential scanning calorimeter, and the instrument control software and analysis software were both built-in software. The sample was heated from 30°C to 350°C at a rate of 10°C / min, and the software recorded the heat changes of the sample during the heating process.

[0041] Thermogravimetric analysis (TGA) data were collected from Mettler Toledo DSC1 / TGA, and the instrument control software and analysis software were built-in software. The sample was heated from 60°C to 400°C at a heating rate of 10°C / min under the protection of 20mL / min dry nitrogen, and the software recorded the weight change of the sample during the heating process.

[0042] Example 1

[0043] Use an analytical balance to accurately weigh temozolomide (5mmol, 0.97g) and nicotinic acid (5mmol, 0.61g) in a 100mL grinding jar, add anhydrous ethanol (0.2mL, 0.158g) with a micropipette, and put in 40g of grinding balls. Put the grinding jar into a planetary ball mill BM6pro, set the speed to 500 rpm, set the grinding time to 5 minutes, and the interval is 3 minutes, and the cycle is repeated 5 times. After the operation is completed, remove the grinding jar, scrape the sample with a clean scraper, and obtain temozolomide-nicotinic acid cocrystal.

[0044] The temozolomide-nicotinic acid cocrystal of the present invention, wherein the molar ratio of temozolomide to nicotinic acid is 1:1, and the X-ray powder diffraction (PXRD) pattern of the temozolomide-nicotinic acid cocrystal measured by Cu-Kα ray is as follows Figure 1 The differential scanning calorimetry (DSC) diagram is shown in Figure 2 As shown in the thermogravimetric analysis (TGA) diagram Figure 3 shown. Figure 1 is the X-ray powder diffraction (PXRD) pattern of the temozolomide-nicotinic acid co-crystal of Example 1. Figure 2 is a differential scanning calorimetry (DSC) chart of the temozolomide-nicotinic acid co-crystal of Example 1. Figure 3 is a thermogravimetric analysis (TGA) chart of the temozolomide-nicotinic acid co-crystal of Example 1.

[0045] From the PXRD spectrum of the prepared temozolomide and nicotinic acid cocrystal, it can be seen that a series of characteristic peaks appear at 10.83±0.2°, 14.66±0.2°, 15.42±0.2°, 17.96±0.2°, 19.07±0.2°, 24.78±0.2°, 25.95±0.2°, 26.54±0.2°, 26.88±0.2°, 27.96±0.2°, 28.75±0.2°, 29.81±0.2°, and 37.99±0.2°. The positions of these characteristic peaks are different from those of the PXRD spectra of both the raw material temozolomide and the precursor nicotinic acid, proving that a new phase is generated.

[0046] As can be seen from the figure, the melting point of the temozolomide and niacin cocrystal is 199.7±2°C (onset temperature), the melting point of niacin is 236.5±2°C, and the melting point of temozolomide is 220.6±2°C. The melting point of the cocrystal is different from the melting points of the raw material and the precursor, proving that a new phase is generated.

[0047] As can be seen from the figure, under the test conditions of nitrogen atmosphere, the thermogravimetric curve of temozolomide-nicotinic acid cocrystal begins to lose weight at 140°C and loses 71% at 400°C. The thermogravimetric curve of temozolomide API begins to lose weight at 160°C and loses 64% at 400°C, which also proves that a new phase is generated.

[0048] Example 2

[0049] Use an analytical balance to accurately weigh temozolomide (5mmol, 0.97g) and nicotinic acid (5mmol, 0.61g) in a 100mL grinding jar, add methanol (0.3mL, 0.238g) with a micropipette, and put in 32g of grinding balls. Put the grinding jar into a planetary ball mill BM6pro, set the speed to 600 rpm, set the grinding time to 4 minutes, and the interval is 2 minutes, and cycle 5 times. After the operation is completed, remove the grinding jar, scrape the sample with a clean scraper, and obtain temozolomide-nicotinic acid cocrystal.

[0050] Example 3

[0051] Use an analytical balance to accurately weigh temozolomide (5mmol, 0.97g) and nicotinic acid (5mmol, 0.61g) in a 100mL grinding jar, add tetrahydrofuran (0.2mL, 0.178g) with a micropipette, and put in 36g of grinding balls. Put the grinding jar into a planetary ball mill BM6pro, set the speed to 500 rpm, set the grinding time to 5 minutes, and the interval is 2 minutes, and the cycle is repeated 3 times. After the operation is completed, remove the grinding jar, scrape the sample with a clean scraper, and obtain temozolomide-nicotinic acid cocrystal.

[0052] Example 4

[0053] Use an analytical balance to accurately weigh temozolomide (5mmol, 0.97g) and nicotinic acid (5mmol, 0.61g) in a 100mL grinding jar, add acetone (0.2mL, 0.158g) with a micropipette, and put in 32g of grinding balls. Put the grinding jar into a planetary ball mill BM6pro, set the speed to 400 rpm, set the grinding time to 5 minutes, and cycle 3 times with an interval of 1 minute. After the operation is completed, remove the grinding jar, scrape the sample with a clean scraper, and obtain temozolomide-nicotinic acid cocrystal.

[0054] Application Example 1

[0055] Solubility determination: Take 100 mg of temozolomide-nicotinic acid cocrystal prepared in Example 1, place it in a 200 ml beaker, add 100 mL of water, place it in a constant temperature heating magnetic stirrer at 25°C ± 2°C, stir for 30 min, let it stand, filter, and take the filtrate as the test solution.

[0056] Preparation of reference solution: Take 50 mg of temozolomide reference substance, add 50 mL of dimethyl sulfoxide, dissolve by ultrasonication and dilute to make a solution containing 1 mg of temozolomide per 1 mL.

[0057] The conditions for HPLC detection were as follows: octadecylsilane bonded silica gel was used as filler, methanol-sodium hexane sulfonate solution was used as mobile phase; the volume ratio of methanol to sodium hexane sulfonate solution was 40:960, the detection wavelength was 270 nm; the column temperature was 30° C., and the injection volume was 10 μL.

[0058] Take 0.94 g of sodium hexane sulfonate, add 0.5% glacial acetic acid solution to dissolve and dilute to 960 ml, mix well to obtain a sodium hexane sulfonate solution.

[0059] Accurately measure the test solution and the reference solution, inject them into the high performance liquid chromatograph respectively, detect according to the above high performance liquid chromatography detection conditions, and record the chromatogram. Calculate the temozolomide content in the test solution and the reference solution by peak area according to the external standard method. The solubility results are shown in Table 1:

[0060] Table 1 Solubility results

[0061]

[0062] As shown in the results in Table 1, the solubility of temozolomide in water is 2.5 mg / mL, and the solubility of the temozolomide-nicotinic acid cocrystal prepared in Example 1 in water is 4.8 mg / mL, which is nearly 2 times higher than the solubility of the temozolomide raw material in water.

[0063] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A temozolomide-nicotinic acid cocrystal, It is characterized in that Temozolomide is used as the active ingredient of the drug, and niacin is used as the cocrystal precursor; The temozolomide-nicotinic acid cocrystal is formed by combining temozolomide and nicotinic acid in a molar ratio of 1:

1.

2. The temozolomide-nicotinic acid cocrystal according to claim 1, It is characterized in that The X-ray powder diffraction spectrum of the temozolomide-nicotinic acid cocrystal measured by Cu-Kα radiation has characteristic peaks at diffraction angles 2θ of approximately 14.66±0.2°, 15.42±0.2°, 26.54±0.2°, and 28.75±0.2°.

3. The temozolomide-nicotinic acid cocrystal according to claim 2, It is characterized in that In the PXRD spectrum, the temozolomide-nicotinic acid cocrystal has characteristic peaks at 2θ angles of approximately 10.83±0.2°, 14.66±0.2°, 15.42±0.2°, 17.96±0.2°, 19.07±0.2°, 24.78±0.2°, 25.95±0.2°, 26.54±0.2°, 26.88±0.2°, 27.96±0.2°, 28.75±0.2°, 29.81±0.2°, and 37.99±0.2°.

4. The temozolomide-nicotinic acid cocrystal according to claim 1, It is characterized in that In the differential scanning calorimetry analysis chart of the temozolomide-nicotinic acid cocrystal, there is a characteristic melting peak at about 199.7±2°C.

5. The temozolomide-nicotinic acid cocrystal according to claim 1, It is characterized in that The thermogravimetric analysis of the temozolomide-nicotinic acid co-crystal showed the following: it began to lose weight at about 140° C. and lost 71% of its weight at about 400° C.

6. A method for preparing the temozolomide-nicotinic acid cocrystal according to any one of claims 1 to 5, It is characterized in that The following steps are involved: Temozolomide and nicotinic acid are mixed at a molar ratio of 1:1, an organic solvent is added, and the mixture is ground with grinding balls to obtain the temozolomide-nicotinic acid cocrystal.

7. The method for preparing the temozolomide-nicotinic acid cocrystal according to claim 6, It is characterized in that The organic solvent is selected from at least one of ethanol, methanol, isopropanol, tetrahydrofuran, acetone and acetonitrile.

8. The method for preparing the temozolomide-nicotinic acid cocrystal according to claim 6, It is characterized in that The mass ratio of the mass of the organic solvent to the total mass of temozolomide and niacin is 0.001 to 0.3:1; The grinding is to put a grinding pot containing temozolomide, nicotinic acid and an organic solvent into a planetary ball mill for grinding.

9. The method for preparing the temozolomide-nicotinic acid cocrystal according to claim 6, It is characterized in that The conditions of the planetary ball mill are as follows: the rotation speed is set to 100 to 1000 rpm, the grinding time is set to 1 to 5 minutes, the interval is 1 to 5 minutes, and the cycle is 1 to 5 times; The mass of the grinding balls is 2 to 100 times the total mass of temozolomide and nicotinic acid.

10. Use of the temozolomide-nicotinic acid cocrystal according to any one of claims 1 to 5 in the preparation of a medicament for treating brain glioma.